ADC Therapeutics Ltd (ADCT) has disclosed a new risk, in the Innovation / R&D category.
ADC Therapeutics Ltd faces considerable business risk due to its lack of control over investigator-initiated clinical trials, such as the recent Phase 2 trial for ZYNLONTA. The company cannot govern the trial designs, oversee the data quality, or manage the regulatory compliance of these studies. This detachment from the process raises concerns about the accuracy and reliability of the clinical data obtained, potentially impacting the company’s ability to make informed decisions and maintain regulatory standards. Without direct oversight, ADC Therapeutics Ltd is vulnerable to data integrity issues that could affect its product development and market trust.
The average ADCT stock price target is $10.20, implying 129.21% upside potential.
To learn more about ADC Therapeutics Ltd’s risk factors, click here.
